Parkinson’s drug therapies in the clinical trial pipeline: 2024 update
Each year, members of the Cure Parkinson’s research team collaborate with Parkinson’s research advocates and The Michael J. Fox Foundation to present an overview on the current clinical trials landscape for Parkinson’s. The 2024 report, now published in the Journal of Parkinson’s Disease (JPD), marks...
Learn more
2023 Tom Isaacs Award honours Dr Natasha Fothergill-Misbah
Cure Parkinson’s and Van Andel Institute (VAI) are delighted to announce Dr Natasha Fothergill-Misbah, Research Associate at Newcastle University, as the winner of the 2023 Tom Isaacs Award. The award was presented to Natasha in Newcastle, as part of the annual Grand Challenges in Parkinson’s…
New research exploring ethnic diversity in Parkinson’s
A recent study from the Global Parkinson’s Genetic Program found a novel genetic risk factor for Parkinson’s in people of African ancestry. This finding once again brings to light the ongoing need for improving diversity in Parkinson’s research.
UK joins Horizon Europe giving access to new research grants
On 7 September, the UK rejoined Horizon Europe, the world’s largest research collaboration programme, with exciting opportunities for research funding and collaboration.
‘Seeing’ the early signs of Parkinson’s
Researchers from University College London and Moorfields Eye Hospital investigated retinal imaging as a potential diagnostic tool for Parkinson’s. The group found changes in the retinas in people with Parkinson’s are detectable years before diagnosis, indicating retinal imaging could be a viable means of identifying disease risk.
The new Multi-arm Multi-stage MAMS trial model for Parkinson’s
One of the most frustrating aspects of the way we currently conduct clinical trials is the long delays between studies. Multi-Arm, Multi-Stage (or MAMS) clinical trials may represent a solution to this cumbersome problem.